Side-by-side comparison of AI visibility scores, market position, and capabilities
Melio is a B2B payments platform enabling small businesses to pay vendors by ACH or card even when vendors only accept checks, improving cash flow management.
Melio is a B2B payments company founded in 2018 in New York that has raised over $500M to modernize accounts payable for small businesses. The platform allows small businesses to pay any vendor by ACH bank transfer or credit card regardless of how the vendor accepts payment, solving the common problem of needing to pay vendors who only accept checks. Melio handles the conversion, sending vendors a check or ACH transfer while the paying business uses their preferred payment method. This approach allows small businesses to earn credit card rewards on vendor payments while preserving cash by paying via card and capturing the float. Melio integrates with QuickBooks Online, Xero, and other accounting software to sync bill payment data automatically. The company serves hundreds of thousands of small businesses and has established embedded payment partnerships with QuickBooks, American Express, and Capital One. Melio charges no subscription fee, generating revenue through optional card payment processing fees. The platform addresses a significant market need given that billions of dollars in B2B payments still move via paper checks in the US.
$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.
ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.